. Author manuscript; available in PMC: 2009 Aug 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):572–576. doi: 10.1097/QAI.0b013e31817bbc4e

Table 1.

Clonal analysis of enfuvirtide resistance mutations in gp41 from plasma virus in subjects undergoing partial treatment interruption.

Subject	Weeks of ENF prior to PTI	Week after PTI	Enfuvirtide resistance mutations at gp41 codons 36–45
1	27	0	V38A, N42T (2/6)^a
			V38A, L44M (4/6)
		16	WT (8/8)
2	33	0	V38A, N42T (8/8)
		16	WT (5/8)
			V38A (2/8)
			N42T (1/8)
		22	WT (9/9)
3	39	0	V38A (7/7)
		17	WT (4/9)
			V38A (5/9)
		24	WT (9/9)

ENF, enfuvirtide; PTI, partial treatment interruption.

No. of clones with indicated sequence/No. of clones sequenced.